Newsletter | August 21, 2026

08.21.26 -- Safeguarding Data Integrity And Exploring Agentic AI

SPONSOR

Join us on August 25th to learn how to optimize Parkinson's disease clinical trials. Experts from Dr. Vince Clinical Research and the Davis Phinney Foundation will discuss trial design, endpoint selection, patient-centered research, and operational challenges for symptomatic and disease-modifying therapies. Attendees will gain practical strategies, real-world case studies, and insights to support successful CNS drug development from early-phase studies through NDA submission.

CLINICAL DATA MANAGEMENT & ANALYTICS

Rare Disease Study Gets A Boost From Crowdsourced Patient Reported Data

Jen A. Levitt, MD, explains how crowdsourced patient-reported data and AI tools can compress rare disease research timelines and surface new signals.

Clinical Trial Data Quality In Neurology Studies

Discover how standardized ocular biomarkers and point-of-need delivery safeguard data integrity in complex neurology trials while keeping patients engaged.

How To Escape The AI Pilot Trap

Agentic AI promises proactive recommendations, cross-functional coordination, and faster decisions, but deploying it effectively requires alignment, oversight, and stakeholder buy-in.

Recognized RTSM Leader: Driving AI Innovation In Clinical Trials

Leadership recognition in a rigorous assessment reflects strong strategy, innovation, and trusted partnerships. AI and platform investments are improving efficiency and advancing clinical trial delivery.

Real-World Data And Real-World Evidence

As clinical research evolves, RWD and RWE play a crucial role in complementing conventional randomized controlled trials (RCTs) by capturing insights that accurately reflect clinical practice.

SPONSOR

Blurb: Webinar: AI Reality Check in Drug Development: What’s Real and What’s Missing

AI is advancing drug discovery and development, but realizing its full potential depends on reliable, high-quality clinical data. Join Dr. Richard Graham, co-founder of TruTechnologies, and industry experts as they explore where AI is delivering value today, where challenges remain, and how sponsors can build the foundation for more effective AI-driven decisions across the drug development lifecycle. Click here to learn more.

TRIAL MONITORING

QA Transitions Don't Create Inspection Risk — They Reveal It

Consultant Wijdan Suliman, MD, MHA, explains how QA leadership changes can reveal risks, including differences in the interpretation, lost historical context, and more.

Monitoring Atrial Fibrillation In Clinical Research

Learn how continuous wearable monitoring can uncover AFib that standard ECGs miss and strengthen trial-grade endpoints.

Governance In Action: Aligning Stakeholders To Safeguard Patients

Strong governance and collaboration among investigators, monitors, and safety teams enhance oversight and enable the protection of patients in clinical trials.

Connect With Clinical Leader: